1-2 of 2
Vikram Singh
Close
Sort by
Journal Articles

CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

Clinical Trials & Observations
Gonzalo Carreño-Tarragona, Alberto Álvarez-Larrán, Claire Harrison, José Carlos Martínez-Ávila, Juan Carlos Hernández-Boluda, Francisca Ferrer-Marín, Deepti H. Radia, Elvira Mora, Sebastian Francis, Teresa González-Martínez, Kathryn Goddard, Manuel Pérez-Encinas, Srinivasan Narayanan, José María Raya, Vikram Singh, Xabier Gutiérrez, Peter Toth, Paula Amat-Martínez, Louisa Mcilwaine, Magda Alobaidi, Karan Mayani, Andrew McGregor, Ruth Stuckey, Bethan Psaila, Adrián Segura, Caroline Alvares, Kerri Davidson, Santiago Osorio, Robert Cutting, Caroline P. Sweeney, Laura Rufián, Laura Moreno, Isabel Cuenca, Jeffery Smith, María Luz Morales, Rodrigo Gil-Manso, Ioannis Koutsavlis, Lihui Wang, Adam J. Mead, María Rozman, Joaquín Martínez-López, Rosa Ayala, Nicholas C. P. Cross
Journal: Blood Advances
Blood Adv (2023) 7 (9): 1672–1681.
https://doi.org/10.1182/bloodadvances.2022008204
Published: 2023
Includes: Supplemental data
Journal Articles

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Clinical Trials & Observations
Michael Northend, William Wilson, Wendy Osborne, Christopher P. Fox, Andrew J. Davies, Dima El-Sharkawi, Elizabeth H. Phillips, Hau Wui Sim, Shalal Sadullah, Nimish Shah, Ying Ying Peng, Iman Qureshi, Juanah Addada, Rocio Figueroa Mora, Neil Phillips, Andrea Kuhnl, Elizabeth Davies, David Wrench, Pamela McKay, Indrani Karpha, Anna Cowley, Richard Karim, Sarah Challenor, Vikram Singh, Cathy Burton, Rebecca Auer, Chris Williams, Joel Cunningham, Angus Broom, Anita Arasaretnam, Claire Roddie, Tobias Menne, William Townsend
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2920–2926.
https://doi.org/10.1182/bloodadvances.2021005953
Published: 2022
Includes: Supplemental data